Literature DB >> 17362293

Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales.

Matthew Hickman1, Peter Vickerman, John Macleod, James Kirkbride, Peter B Jones.   

Abstract

AIMS: To estimate long-term trends in cannabis use and projections of schizophrenia assuming a causal relation between cannabis use and schizophrenia.
METHODS: Trends in cannabis use were estimated from a national survey, 2003; and incidence of schizophrenia was derived from surveys in three English cities, 1997-99. A difference equation cohort model was fitted against estimates of schizophrenia incidence, trends in cannabis exposure and assumptions on association between cannabis and schizophrenia. The model projects trends in schizophrenia incidence, prevalence and attributable fraction of cannabis induced schizophrenia.
RESULTS: Between 1970 and 2002 cannabis exposure increased: incidence by fourfold; period prevalence by 10-fold; and use among under 18-year-olds by 18-fold. In 1997-99 incidence and prevalence of schizophrenia were 17 per 100 000 and 0.63% among men and 7.3 per 100 000 and 0.23% among women, respectively. If cannabis use causes schizophrenia, earlier increases in cannabis use would lead to increases in overall schizophrenia incidence and prevalence of 29% and 12% among men between 1990 and 2010. By 2010 model projections which assume an association between schizophrenia and light and heavy users suggest that approximately one-quarter of new schizophrenia cases could be due to cannabis, whereas if the association is twofold and confined to heavy cannabis users, then approximately 10% of schizophrenia cases may be due to cannabis.
CONCLUSIONS: If cannabis use causes schizophrenia, and assuming other causes are unchanged, then relatively substantial increases in both prevalence and incidence of schizophrenia should be apparent by 2010. More accurate data on cannabis consumption and future monitoring of schizophrenia are critical.

Entities:  

Mesh:

Year:  2007        PMID: 17362293     DOI: 10.1111/j.1360-0443.2006.01710.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  19 in total

1.  Incidence of hospitalised schizophrenia in Finland since 1980: decreasing and increasing again.

Authors:  Raimo K R Salokangas; Mika Helminen; Anna-Maija Koivisto; Helena Rantanen; Hannu Oja; Sami Pirkola; Kristian Wahlbeck; Matti Joukamaa
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-03-20       Impact factor: 4.328

2.  Will use of cannabis increase more rapidly with legalization than during prohibition?

Authors:  Thomas Kjøsnes
Journal:  CMAJ       Date:  2019-01-21       Impact factor: 8.262

Review 3.  Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models.

Authors:  Daniel T Malone; Matthew N Hill; Tiziana Rubino
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

4.  Effects of eye dominance (left vs. right) and cannabis use on intermanual coordination and negative symptoms in schizophrenia patients.

Authors:  Inge Gorynia; Markus Schwaiger; Andreas Heinz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-05-04       Impact factor: 5.270

5.  Changes in alcohol and cigarette consumption in response to medical and recreational cannabis legalization: Evidence from U.S. state tax receipt data.

Authors:  Sirish Veligati; Seth Howdeshell; Sara Beeler-Stinn; Deepak Lingam; Phylicia C Allen; Li-Shiun Chen; Richard A Grucza
Journal:  Int J Drug Policy       Date:  2019-11-15

6.  Cannabis use and the risk of developing a psychotic disorder.

Authors:  Wayne Hall; Louisa Degenhardt
Journal:  World Psychiatry       Date:  2008       Impact factor: 49.548

7.  Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed.

Authors:  Margaret Haney; A Eden Evins
Journal:  Neuropsychopharmacology       Date:  2015-08-19       Impact factor: 7.853

8.  The role of cannabis in cognitive functioning of patients with schizophrenia.

Authors:  Thomas Schnell; Dagmar Koethe; Jörg Daumann; Euphrosyne Gouzoulis-Mayfrank
Journal:  Psychopharmacology (Berl)       Date:  2009-03-27       Impact factor: 4.530

9.  Genetic Predisposition vs Individual-Specific Processes in the Association Between Psychotic-like Experiences and Cannabis Use.

Authors:  Nicole R Karcher; Deanna M Barch; Catherine H Demers; David A A Baranger; Andrew C Heath; Michael T Lynskey; Arpana Agrawal
Journal:  JAMA Psychiatry       Date:  2019-01-01       Impact factor: 21.596

10.  Should burden of disease estimates include cannabis use as a risk factor for psychosis?

Authors:  Louisa Degenhardt; Wayne D Hall; Michael Lynskey; John McGrath; Jennifer McLaren; Bianca Calabria; Harvey Whiteford; Theo Vos
Journal:  PLoS Med       Date:  2009-09-29       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.